Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension. A pilot study

Peter Tamás, Tamás Csermely, Tibor Ertl, Miklós Vizer, I. Szabó, Ferenc T. Prievara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To test the effects of calcium dobesilate (Doxium) in pregnancies complicated with pregnancy-induced hypertension or mild/moderate pre-eclampsia a double-blind, placebo-controlled pilot study was carried out. Primigravida patients (gestational age ≤ 34 weeks) daily took 2 g Doxium or placebo until delivery. Twelve patients received placebo for 53 days, and 11 patients took the drug for 57 days on average. At the start of the study 2 patients in the placebo group (PG) and 8 in the Doxium group (DG) had pre-eclampsia. The mean arterial pressure (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mm Hg in the DG (p = 0.003), while in the PG it had slightly increased by the end of the study. Proteinuria was higher in the DG at the start but not at the end; however, significant changes of this parameter were detected in neither of the groups throughout the study. Fibronectin decreased significantly in both groups but it was more pronounced in the DG (23.8 vs. 9.4%). Changes of platelet count, plasma and blood viscosity, and erythrocyte deformability were favourable in the DG but in the PG these parameters had deteriorated although the alterations were not significant. No marked differences were found between the two groups regarding fetal well-being, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. It seems that Doxium favourably influences the blood pressure and consequently decreases the requirement for medication and hospitalisation in cases of mild to moderate midtrimester hypertension.

Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalGynecologic and Obstetric Investigation
Volume47
Issue number3
Publication statusPublished - 1999

Fingerprint

Calcium Dobesilate
Second Pregnancy Trimester
Blood Pressure
Hypertension
Placebos
Pre-Eclampsia
Erythrocyte Deformability
Pregnancy Induced Hypertension
Blood Viscosity
Platelet Count
Proteinuria
Fibronectins
Gestational Age
Arterial Pressure
Hospitalization

Keywords

  • Calcium dobesilate
  • Hypertension, gestational
  • Microcirculation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension. A pilot study. / Tamás, Peter; Csermely, Tamás; Ertl, Tibor; Vizer, Miklós; Szabó, I.; Prievara, Ferenc T.

In: Gynecologic and Obstetric Investigation, Vol. 47, No. 3, 1999, p. 210-213.

Research output: Contribution to journalArticle

Tamás, Peter ; Csermely, Tamás ; Ertl, Tibor ; Vizer, Miklós ; Szabó, I. ; Prievara, Ferenc T. / Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension. A pilot study. In: Gynecologic and Obstetric Investigation. 1999 ; Vol. 47, No. 3. pp. 210-213.
@article{b8c105d829e04d68aa9e6359744d4c5b,
title = "Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension. A pilot study",
abstract = "To test the effects of calcium dobesilate (Doxium) in pregnancies complicated with pregnancy-induced hypertension or mild/moderate pre-eclampsia a double-blind, placebo-controlled pilot study was carried out. Primigravida patients (gestational age ≤ 34 weeks) daily took 2 g Doxium or placebo until delivery. Twelve patients received placebo for 53 days, and 11 patients took the drug for 57 days on average. At the start of the study 2 patients in the placebo group (PG) and 8 in the Doxium group (DG) had pre-eclampsia. The mean arterial pressure (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mm Hg in the DG (p = 0.003), while in the PG it had slightly increased by the end of the study. Proteinuria was higher in the DG at the start but not at the end; however, significant changes of this parameter were detected in neither of the groups throughout the study. Fibronectin decreased significantly in both groups but it was more pronounced in the DG (23.8 vs. 9.4{\%}). Changes of platelet count, plasma and blood viscosity, and erythrocyte deformability were favourable in the DG but in the PG these parameters had deteriorated although the alterations were not significant. No marked differences were found between the two groups regarding fetal well-being, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. It seems that Doxium favourably influences the blood pressure and consequently decreases the requirement for medication and hospitalisation in cases of mild to moderate midtrimester hypertension.",
keywords = "Calcium dobesilate, Hypertension, gestational, Microcirculation",
author = "Peter Tam{\'a}s and Tam{\'a}s Csermely and Tibor Ertl and Mikl{\'o}s Vizer and I. Szab{\'o} and Prievara, {Ferenc T.}",
year = "1999",
language = "English",
volume = "47",
pages = "210--213",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension. A pilot study

AU - Tamás, Peter

AU - Csermely, Tamás

AU - Ertl, Tibor

AU - Vizer, Miklós

AU - Szabó, I.

AU - Prievara, Ferenc T.

PY - 1999

Y1 - 1999

N2 - To test the effects of calcium dobesilate (Doxium) in pregnancies complicated with pregnancy-induced hypertension or mild/moderate pre-eclampsia a double-blind, placebo-controlled pilot study was carried out. Primigravida patients (gestational age ≤ 34 weeks) daily took 2 g Doxium or placebo until delivery. Twelve patients received placebo for 53 days, and 11 patients took the drug for 57 days on average. At the start of the study 2 patients in the placebo group (PG) and 8 in the Doxium group (DG) had pre-eclampsia. The mean arterial pressure (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mm Hg in the DG (p = 0.003), while in the PG it had slightly increased by the end of the study. Proteinuria was higher in the DG at the start but not at the end; however, significant changes of this parameter were detected in neither of the groups throughout the study. Fibronectin decreased significantly in both groups but it was more pronounced in the DG (23.8 vs. 9.4%). Changes of platelet count, plasma and blood viscosity, and erythrocyte deformability were favourable in the DG but in the PG these parameters had deteriorated although the alterations were not significant. No marked differences were found between the two groups regarding fetal well-being, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. It seems that Doxium favourably influences the blood pressure and consequently decreases the requirement for medication and hospitalisation in cases of mild to moderate midtrimester hypertension.

AB - To test the effects of calcium dobesilate (Doxium) in pregnancies complicated with pregnancy-induced hypertension or mild/moderate pre-eclampsia a double-blind, placebo-controlled pilot study was carried out. Primigravida patients (gestational age ≤ 34 weeks) daily took 2 g Doxium or placebo until delivery. Twelve patients received placebo for 53 days, and 11 patients took the drug for 57 days on average. At the start of the study 2 patients in the placebo group (PG) and 8 in the Doxium group (DG) had pre-eclampsia. The mean arterial pressure (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mm Hg in the DG (p = 0.003), while in the PG it had slightly increased by the end of the study. Proteinuria was higher in the DG at the start but not at the end; however, significant changes of this parameter were detected in neither of the groups throughout the study. Fibronectin decreased significantly in both groups but it was more pronounced in the DG (23.8 vs. 9.4%). Changes of platelet count, plasma and blood viscosity, and erythrocyte deformability were favourable in the DG but in the PG these parameters had deteriorated although the alterations were not significant. No marked differences were found between the two groups regarding fetal well-being, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. It seems that Doxium favourably influences the blood pressure and consequently decreases the requirement for medication and hospitalisation in cases of mild to moderate midtrimester hypertension.

KW - Calcium dobesilate

KW - Hypertension, gestational

KW - Microcirculation

UR - http://www.scopus.com/inward/record.url?scp=0032971124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032971124&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 210

EP - 213

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 3

ER -